About MIDAS™

MIDAS™ is the first rational synthetic chemistry platform for the rapid conversion of peptides into therapeutics. MIDAS™ can quickly generate both receptor agonists (drugs that promote a particular response) and receptor antagonists (drugs that block a particular response), setting it apart from traditional structure-based drug design methods. A key feature of MIDAS™ is its ability to quickly and easily identify, and then stabilize, a desired conformation of a peptide for a specific drug target. Palatin is utilizing this novel, patented technology to build an internal portfolio of viable drug candidates.

MIDAS™ Benefits:

• "Speed to Lead": Reduces the time required to produce a qualified lead molecule in the drug development process
• Generates highly qualified, focused sets of compounds, eliminating the need for costly high throughput screening
• Generates and locks the bioactive conformation of a peptide
• Directly facilitates structure based design of traditional small molecule drugs
• Generates chemically and proteolytically stable structures
• Ability to characterize pharmacologically active structures
• Uniquely generates receptor agonists and receptor antagonists
• Offers potential for oral bioavailability